MMP-01: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody With High Dose IL-2 in Metastatic Melanoma

Trial Profile

MMP-01: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody With High Dose IL-2 in Metastatic Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2018

At a glance

  • Drugs Interleukin-2 (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2018 Planned End Date changed from 1 Apr 2022 to 1 May 2022.
    • 09 May 2018 Planned primary completion date changed from 1 Apr 2021 to 1 May 2021.
    • 09 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top